Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7198413 | 0.82 | MEN1 (0.39) | — | |
| SCHEMBL7201462 | 0.80 | ODC1 (0.34) | — | |
| SCHEMBL11410701 | 0.80 | TSHR (0.41) | — | |
| SCHEMBL7201464 | 0.80 | ODC1 (0.34) | — | |
| SCHEMBL11476306 | 0.79 | — | — | |
| SCHEMBL7202563 | 0.79 | GGT1 (0.35) | GRM4 | |
| SCHEMBL7201403 | 0.77 | GABRP (0.33) | — | |
| SCHEMBL11404255 | 0.77 | TSHR (0.45) | — | |
| SCHEMBL27593961 | 0.77 | GABRP (0.33) | — | |
| SCHEMBL11409788 | 0.76 | TSHR (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602910-B2 | Treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine | ILEX ONCOLOGY, INC. | 2003-08-05 | — | — | US | disclosed |
| EP-1261326-A1 | D-ENANTIOMER OF DFMO AND METHODS OF USE THEREFOR FOR TREATING CANCER | Ilex Oncology, Inc. (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | ILEX ONCOLOGY, INC. (US) | 2002-04-18 | — | — | US | disclosed |
| WO-2001068076-A2 | D-ENANTIOMER OF DFMO AND METHODS OF USE THEREOF FOR TREATING CANCER | ILEX ONCOLOGY, INC. (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | DHODH, DDT, HADHB | GRM4 3887/4885DGAT1 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.